Abstract
All children without contraindications should receive two doses of measles-mumps-rubella combination vaccine (abbreviation: MMR; trade name: M-M-R II®) after 1 year of age and at least 4 weeks apart. The first dose is usually administered at a minimum of 12 months of age, and is generally given between 12 and 15 months of age. The second dose is usually given between 4 and 6 years of age, prior to entering school, although it can be given anytime at least 4 weeks after the first dose for children at increased risk of exposure. The CDC recommends that MMR and varicella vaccine (trade name: Varivax®) be administered separately for the first dose in order to reduce the small increased risk of febrile seizures in toddlers associated with the measles-mumps-rubella-varicella combination vaccine (abbreviation: MMRV; trade name: ProQuad®) compared to the separate but simultaneous administration of MMR and varicella vaccines. MMRV is generally preferred for the second dose. One dose of MMR should be administered to all adults 18 years of age and older without evidence of immunity to these diseases (acceptable evidence of immunity includes documentation of previous receipt of MMR or MMRV vaccine, laboratory confirmation of immunity or disease, or having been born before 1957). Two doses separated by at least 4 weeks are recommended for adults at high risk for exposure and transmission (such as international travelers; college students; and health care personnel). Persons previously vaccinated with two doses of a mumps-containing vaccine who are identified by public health as at increased risk for mumps because of an outbreak should receive a third dose of a mumps-containing vaccine to improve protection against mumps disease and related complications.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Epidemiology and Prevention of Vaccine-Preventable Diseases, K.A. Hamborsky J, Wolfe S Editor. 2015, Centers for Disease Control and Prevention: Washington D.C.
McLean, H.Q., et al., Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep, 2013. 62(RR-04): p. 1–34.
Marin, M., et al., Recommendation of the Advisory Committee on Immunization Practices for Use of a Third Dose of Mumps Virus-Containing Vaccine in Persons at Increased Risk for Mumps During an Outbreak. MMWR Morb Mortal Wkly Rep, 2018. 67(1): p. 3–38.
Kroger, A.T., J. Duchin, and M. Vázquez. General Best Practice Guidelines for Immunization. Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP). 2017 [cited 2017 October]; Available from: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html.
Demicheli, V., et al., Vaccines for measles, mumps and rubella in children. Cochrane Database Syst Rev, 2012. 2: p. Cd004407.
Cardemil, C.V., et al., Effectiveness of a Third Dose of MMR Vaccine for Mumps Outbreak Control. N Engl J Med, 2017. 377(10): p. 947–56.
Cortese, M.M. and U.D. Parashar, Prevention of rotavirus gastroenteritis among infants and children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep, 2009. 58(Rr-2): p. 1–25.
Briere, E.C., Food and Drug Administration Approval for Use of Hiberix as a 3-Dose Primary Haemophilus influenzae Type b (Hib) Vaccination Series. MMWR Morb Mortal Wkly Rep, 2016. 65(16): p. 418–9.
Briere, E.C., et al., Prevention and control of haemophilus influenzae type b disease: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep, 2014. 63(Rr-01): p. 1–14.
(AAP), A.A.o.P., Neurodiagnostic evaluation of the child with a simple febrile seizure. Pediatrics, 2011. 127(2): p. 389–94.
(AAP), A.A.o.P., Febrile seizures: clinical practice guideline for the long-term management of the child with simple febrile seizures. Pediatrics, 2008. 121(6): p. 1281–6.
Bonhoeffer, J., et al., Generalized convulsive seizure as an adverse event following immunization: case definition and guidelines for data collection, analysis, and presentation. Vaccine, 2004. 22(5–6): p. 557–62.
Tse, A., et al., Signal identification and evaluation for risk of febrile seizures in children following trivalent inactivated influenza vaccine in the Vaccine Safety Datalink Project, 2010–2011. Vaccine, 2012. 30(11): p. 2024–31.
Klein, N.P., et al., Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures. Pediatrics, 2010. 126(1): p. e1–8.
Centers for Disease Control and Prevention. Vaccine Information Statements (VIS). August 7, 2015 [cited 2015; Available from: http://www.cdc.gov/vaccines/hcp/vis/current-vis.html.
Badilla, X., et al., Fetal risk associated with rubella vaccination during pregnancy. Pediatr Infect Dis J, 2007. 26(9): p. 830–5.
Castillo-Solorzano, C., et al., Rubella vaccination of unknowingly pregnant women during mass campaigns for rubella and congenital rubella syndrome elimination, the Americas 2001–2008. J Infect Dis, 2011. 204 Suppl 2: p. S713–7.
Soares, R.C., et al., Follow-up study of unknowingly pregnant women vaccinated against rubella in Brazil, 2001–2002. J Infect Dis, 2011. 204 Suppl 2: p. S729–36.
da Silva e Sa, G.R., et al., Pregnancy outcomes following rubella vaccination: a prospective study in the state of Rio de Janeiro, Brazil, 2001–2002. J Infect Dis, 2011. 204 Suppl 2: p. S722–8.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Dudley, M.Z. et al. (2018). Measles, Mumps and Rubell (MMR). In: The Clinician’s Vaccine Safety Resource Guide. Springer, Cham. https://doi.org/10.1007/978-3-319-94694-8_12
Download citation
DOI: https://doi.org/10.1007/978-3-319-94694-8_12
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-94693-1
Online ISBN: 978-3-319-94694-8
eBook Packages: MedicineMedicine (R0)